EVALUATION OF NEW ANTIINFECTIVE DRUGS FOR THE TREATMENT OF DIARRHEA CAUSED BY GIARDIA-LAMBLIA

被引：8

作者：

COOPERSTOCK, M

DUPONT, HL

CORRADO, ML

FEKETY, R

MURRAY, DM

机构：

[1] UNIV TEXAS,SCH MED,HLTH SCI CTR HOUSTON,CTR INFECT DIS,6431 FANNIN,1 728 JFB,HOUSTON,TX 77030

[2] UNIV TEXAS,SCH PUBL HLTH,HOUSTON,TX 77025

[3] UNIV MISSOURI,MED CTR,SCH MED,DEPT PEDIAT,COLUMBIA,MO 65201

[4] ROBERT WOOD JOHNSON PHARMACEUT INST,DIV ANTIINFECT,RARITAN,NJ

[5] UNIV MICHIGAN,MED CTR,DIV INFECT DIS,ANN ARBOR,MI 48109

[6] PROCTER & GAMBLE CO,GEN OFF HLTH CARE,CINCINNATI,OH 45239

来源：

CLINICAL INFECTIOUS DISEASES | 1992年 / 15卷

关键词：

D O I：

10.1093/clind/15.Supplement_1.S244

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Giardia lamblia is a flagellate protozoan that produces symptoms by infecting the small bowel and biliary tract in the trophozoite form. Diagnosis is currently established by microscopic visualization of the organism in appropriate intestinal contents (stool, small-bowel contents, or biopsy specimen). Adult patients with diarrhea and one or more enteric symptoms may be enrolled in clinical trials of new drugs for the treatment of giardial disease. A randomized, double-blind, active-concurrent-control design is recommended. Post hoc stratification by age, immune status, chronicity of disease, and ease of establishing diagnosis (organism load) may be performed. Microbiological assessment 48 hours to 7 days after the completion of therapy is paramount for determining final outcome.

引用

页码：S244 / S248

页数：5